Drugs Made In America Acquisition Corp
DMAA
39 hedge funds and large institutions have $232M invested in Drugs Made In America Acquisition Corp in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
5% more funds holding
Funds holding: 37 → 39 (+2)
2.63% more ownership
Funds ownership: 64.91% → 67.55% (+2.6%)
4% more capital invested
Capital invested by funds: $223M → $232M (+$8.63M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCS
Mercuria Capital Strategies
Houston,
Texas
|
+$7.74M |
| 2 |
MSU
Mizuho Securities USA
New York
|
+$3.44M |
| 3 |
QL
Quarry LP
New York
|
+$2.59M |
| 4 |
GL
Governors Lane
New York
|
+$2.47M |
| 5 |
CS
Clear Street
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$3.1M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$2.58M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$1.59M |
| 4 |
JP Morgan Chase
New York
|
-$515K |
| 5 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
-$161K |
DMAA Hedge Fund Activity: Q4 2025 in Review
39 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp (DMAA) for Q4 2025, worth a combined $232M — up 3.9% from $223M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new DMAA positions and 1 closed out — a net gain of 3 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Mercuria Capital Strategies, opening a new position worth an estimated $7.74M. The largest seller was Polar Asset Management Partners, cutting an estimated $3.1M.
- 39 institutional investors held Drugs Made In America Acquisition Corp (DMAA) as of Q4 2025, up from 37 in Q3 2025.
- Funds reported $232M of Drugs Made In America Acquisition Corp stock for Q4 2025, up 3.9% quarter-over-quarter.
- 4 funds opened new Drugs Made In America Acquisition Corp positions in Q4 2025 and 1 closed out, a net change of +3 holders.
- The largest Drugs Made In America Acquisition Corp buyer in Q4 2025 was Mercuria Capital Strategies, an estimated $7.74M added.
- The largest Drugs Made In America Acquisition Corp seller in Q4 2025 was Polar Asset Management Partners, an estimated $3.1M sold.
Based on aggregated 13F filings for Q4 2025.